テルイ　ヤスヒト   TERUI Yasuhito   照井　康仁    所属   埼玉医科大学  医学部 血液内科    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma
掲載誌名	正式名：Cancer Sci ISSNコード：13497006
掲載区分	国外
巻・号・頁	112,2426-2435頁
著者・共著者	Kawai, H., Ando, K., Maruyama, D., Yamamoto, K., Kiyohara, E., Terui, Y., Fukuhara, N., Miyagaki, T., Tokura, Y., Sakata-Yanagimoto, M., Igarashi, T., Kuroda, J., Fujita, J., Uchida, T., Ishikawa, T., Yonekura, K., Kato, K., Nakanishi, T., Nakai, K., Matsunaga, R., Tobinai, K.
発行年月	2021
概要	It shares an amino acid sequence with denileukin diftitox, but has improved purity and an increased percentage of active monomer. Among the 36 patients with PTCL and CTCL, objective response rate based on the independent review was 36%. The median progression-free survival was 3.1 months . The common AEs observed were increased AST/ ALT, hypoalbuminemia, lymphopenia, and pyrexia. Our results indicated that a 9 µg/kg/d dose of E7777 shows efficacy and a manageable safety profile in Japanese patients with relapsed or refractory PTCL and CTCL, with clinical activity observed across the range of CD25 expression. The common AEs were manageable, but increase in ALT / AST, hypoalbuminemia, and capillary leak syndrome should be carefully managed during the treatment.
DOI	10.1111/cas.14906
文献番号	33792128